



Hereford Funds

Signatory of:



Bin Yuan Healthcare Fund

SFDR status as of March 2021: Article 8

May 2025

RACE TO ZERO

Investment Review

The Hereford Funds – Bin Yuan Healthcare Fund (share class L1) increased 5.68% for the month of May (net of fees) compared with a 5.89% return for the benchmark. As of the end of May, the Sub Fund was mainly invested in Healthcare Equipment & Parts and Biotechnology, with few positions in the Services sector.

For the month, the Fund underperformed the benchmark by 21bps. Positions that contributed most to the portfolio were INNOVENT BIOLOGI, CSPC PHARMACEUTI and JIANGSU YUYUE. Positions that contributed least were BEIGENE LTD, AKESO INC and APT MEDICAL.

Manager's Commentary

This month, top holding and top contributor of our portfolio **Innovent** (1801.HK) continued to deliver robust performance, with Q1 product revenue reaching RMB 2.4 billion (+40% YoY, +14% QoQ).

At recent ASCO (American Society of Clinical Oncology), Innovent presented clinical data for its multiple pipeline assets: IBI343 (CLDN18.2 ADC): Phase 1 second-line data showed mOS (median overall survival) of 12.1 months in treating advanced pancreatic cancer, significantly surpassing the 6-month benchmark of 5-FU-based regimens. Excellent clinical data promises to bring new hope to second-line pancreatic cancer patients lacking treatment options. IBI363 (PD-1/IL-2α-bias): Achieved a mOS of 15.3 months in the low-dose group for immunotherapy-resistant squamous non-small cell lung cancer (NSCLC) and 17.5 months in the low-dose group for immunotherapy-resistant lung adenocarcinoma. Both results surpassed the 9-month mOS of traditional chemotherapy regimens. With higher-dose group data yet to mature, further improvements are anticipated. This agent is poised to become a core later-line regimen following PD-1/PD-L1 inhibitor therapy.

In recent years, global recognition of China's innovative drugs has steadily increased. The proportion of Chinese innovative drugs in MNC (Multinational Corporation) product pipelines has risen from 13% in 2022 to 33% in 2024. With its robust product portfolio, Innovent is poised to attract greater attention from MNCs. Further clinical progress may enable pipeline out-licensing deals, bolstering cash flow.

The company's flagship product Mazdutide (GLP-1R/GCGR) is nearing approval. With China's GLP-1 drug market projected to peak at RMB 40 billion, we forecast Mazdutide sales will exceed RMB 7 billion by 2028. **This is expected to drive Innovent's 2028 revenue beyond RMB 24 billion and profits over RMB 5.9 billion, implying a market cap of RMB 205 billion (+90% upside).** Even more impressively, this product not only demonstrates outstanding data in weight loss and diabetes management, but also shows therapeutic potential in areas such as Obstructive Sleep Apnea (OSA) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), promising new growth opportunities in the future.

Key Information

NAV (31/5/25) US\$ 58.57(L1)
Total Fund Size US\$ 2.2m

Strategy Assets US\$ 2.2 m^(a)
Fund Launch Date 03-Dec-21

Monthly Performance (%) data from FPS/Pictet

									2025						ITD
	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	Jan	Feb	Mar	Apr	May	YTD	
Bin Yuan HC Fund	-6.98	-0.81	-0.76	15.99	-10.07	0.36	-3.01	-21.31	-0.85	3.88	-0.43	-0.09	5.68	8.28	-41.43
Index ^(b)	-3.84	4.08	3.30	22.74	-10.99	0.33	-4.87	-18.94	0.99	11.21	6.57	-0.06	5.89	26.67	-44.05

Source: Bin Yuan, Pictet, FPS

Risk and reward profile

Lower risk

Potentially lower reward

Higher risk

Potentially higher reward



The risk indicator assumes you keep the product for 4 years. We have classified this product as 6 out of 7, which is the second –highest risk. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact our capacity to pay you.

Please refer to the prospectus^(d) for more information on the specific risks relevant to this product not included in the summary risk indicator. This product does not include any protection from future market performance, so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.

Top Ten Holding					
1	INNOVENT BIOLOGI	8.99%	2	BEIGENE LTD	8.63%
3	JIANGSU YUYUE-A	6.39%	4	AK MEDICAL HOLDI	5.88%
5	SHANGHAI UNITE-A	5.22%	6	ZHEJIANG XIAN-A	4.77%
7	SHENZHEN MINDR-A	4.63%	8	CSPC PHARMACEUTI	4.32%
9	AKESO INC	4.13%	10	KANGJI MEDICAL H	3.75%

Investment Objective

The investment objective of the Compartment is to provide long term capital growth, measured in USD, primarily through investment in equities and equity-linked securities of Greater China Companies, as defined hereafter.

Market Breakdown	% of Assets
A Share	43
Hong Kong (Discounted Dual Listing)	11
Hong Kong	39

Sectoral Breakdown	% of Assets
Healthcare Equipment & Parts	41
Biotechnology	27
Pharmaceuticals	16
Services	9

Valuation ^(c)	Portfolio	Benchmark
Period	5/31/2025	5/31/2025
2025 PE (X) – Weighted Avg. Method	18.4	19.1
2025 PE (X) – Harmonic Avg. Method ^(c)	22.0	31.8
2025 PB (X)	2.6	2.9
2025 Div. Yield (%)	1.3	1.1
2025 ROE (%)	14.1	9.3
Earning Growth (%) Forward 3 YR	24.7	14.5
2025 PEGY	0.7	1.2
FCF Yield	0.8	0.9

The Sub-Fund is actively managed. The benchmark index of the Sub-Fund is MSCI China Health Care Index. It is used for the calculation of the performance fee and for performance comparison purposes. The Investment Manager is not in any way constrained by the benchmark index in its portfolio positioning. This means the Investment Manager is taking investment decisions without reference to a benchmark index. The Sub-Fund can deviate significantly from the index.

Annual Management Charge TERs as at end September 2021	
Share Class L1	0.50% NA
Share Class A	1.00% NA
Share Class P	0.50% with 10% Performance Fee NA
Minimum Investment	
Share Class L1	\$100,000 Minimum initial subscription & holding
Share Class A	\$100,000 Minimum initial subscription & holding
Share Class P	\$100,000 Minimum initial subscription & holding

Fund Codes	
Share Class	L1
Bloomberg	HEFYHUA LX
TK	
ISIN	LU2413982427
Lipper ID	
Sedol	BLBHZ45

Entry / Exit fees ; 0

All the costs are not disclosed into the factsheet, please refer to the prospectus for additional information.

Fund Details	
Dealing Day	Daily
Dividends	None – income accumulated within the fund
Investment Manager	Bin Yuan Capital Room 1505, 15/F, 299QRC 287-299 Queen's Road Central Sheung Wan, Hong Kong
Management Company	HF Arode Asset Management S.A. 93, Route d'Arlon , L-1140 Luxembourg
Custodian	Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg 15, Avenue John F Kennedy, L-1855 Luxembourg
Legal Advisors	Elvinger Hoss Prussen S.A. 2, Place Winston Churchill, L-1340 Luxembourg
Auditor	Deloitte Audit S.à r.l. 560, route de Neudorf, L-2220 Luxembourg

Fund Codes	
Share Class	L1
Bloomberg	HEFYHUA LX
TK	
ISIN	LU2413982427
Lipper ID	
Sedol	BLBHZ45

Order Transmission Information

Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg
15, Avenue John F Kennedy,
L-1855 Luxembourg
Via fax +352 46 71 71 7667 or SWIFT PICTLULXTAS

Footnote:

(a) This refers to the total assets invested in the reference strategy managed by the Investment Manager.

(b) MSCI China Health Care Index (Bloomberg Ticker MXCN0HC Index).

(c) The harmonic average, also known as the harmonic mean, is a type of average that is useful in situations where calculating an average rate or ratio. It's particularly effective when the values we are averaging are defined in terms of a ratio of two quantities (like speed, which is distance per unit of time).

The formula for the harmonic average is:

Harmonic Mean = $N / \sum (1/Value_i)$

Where:

- (N) is the total number of values.

- $\sum (1/Value_i)$ is each individual value in the set.

(d) Prospectus (English) and KIDS (English, French, German)

Disclaimer:

- This document should be read as a marketing communication.
- Risk Disclaimer - This current risk profile is based on historical data and may not be a reliable indication of the future risk profile of the Sub-Fund. - The risk category shown is not guaranteed and may shift over time. - The lowest category, which corresponds to Number 1, cannot be regarded as being risk-free. - The Sub-Fund does not provide any capital guarantee or asset protection measures. Why is this Sub-Fund in this category? The investment objective of the Sub-Fund is to generate long-term capital growth and income by investing in equities and equity-linked securities of Greater China Companies. Hence, the risk/reward profile of the SubFund should correspond to a high risk category on the risk/reward scale. The contents of this document are communicated by, and the property of, Hereford Funds. This document is for information purposes and internal use only. It is neither an advice nor a recommendation to enter into any investment. Investment suitability must be determined individually for each investor, and the financial instruments described above may not be suitable for all investors. This information does not provide any accounting, legal, regulatory or tax advice. Please consult your own professional advisers in order to evaluate and judge the matters referred to herein. An investment should be made only on the basis of the prospectus, the annual and any subsequent semi-annual reports of HEREFORD FUNDS (the "Fund"), a société d'investissement à capital variable, established in Luxembourg and registered under Part I of Luxembourg law of 20 December, approved by the Commission de Surveillance du Secteur Financier (CSSF). These can be obtained from the Fund, from FundPartner Solutions (Europe) SA, 15 avenue J. F. Kennedy, L-1855 Luxembourg, and any distributor or intermediary appointed by the Fund. You can obtain a summary of investors rights to the following link : <https://www.group.pictet/media/sd/176b100ab205a6e6aef82b0250138f889675b903>
- No warranty is given, in whole or in part, regarding performance of the Fund. There is no guarantee that its investment objectives will be achieved. Potential investors shall be aware that the value of investments can fall as well as rise and that they may not get back the full amount invested. Past performance is no guide to future performance. Future Performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. Returns may increase or decrease as a result of currency fluctuations. The information provided in this document may be subject to change without any warning or prior notice and should be read in conjunction with the most recent publication of the prospectus of the Fund. Whilst great care is taken to ensure that information contained herein is accurate, no responsibility can be accepted for any errors, mistakes or omission or for future returns. This document is intended for the use of the addressee or recipient only and may not be reproduced, redistributed, passed on or published, in whole or in part, for any purpose, without the prior written consent of HEREFORD FUNDS. Neither the CSSF nor any other regulator has approved this document.
- According to the SFC climate-related disclosure requirement, please find our disclosure of [Management and Disclosure of Climate-related Risks by Fund Managers](#).
- Marketing communications should indicate that the decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus.